Brief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia

John M Salsman, Jennifer L Beaumont, Katy Wortman, Ying Yan, John Friend, David Cella, John M Salsman, Jennifer L Beaumont, Katy Wortman, Ying Yan, John Friend, David Cella

Abstract

Purpose: Cancer anorexia-cachexia syndrome (CACS) is common in advanced cancer patients and associated with weight loss, fatigue, impaired quality of life (QoL), and poor prognosis. The goal of this project was to identify the most responsive items from two QoL measures in the ROMANA 2 (NCT01387282) phase III global study evaluating anamorelin HCl in the treatment of non-small cell lung cancer (NSCLC) cachexia: the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and the Functional Assessment of Anorexia/Cachexia Therapy (FAACT).

Methods: In the ROMANA 2 trial, 477 patients with unresectable stage III or IV NSCLC and cachexia were to be enrolled and randomized (2:1) to receive anamorelin HCl or placebo once daily for 12 weeks. All 203 patients who reached the week 12 visit at the time of data analysis were included. Co-primary endpoints were change from baseline in lean body mass and handgrip strength. QoL was a secondary outcome with FACIT-F and FAACT questionnaires administered at baseline and at weeks 3, 6, 9, and 12.

Results: Two 4-item scales (fatigue/activity and appetite/eating) from the FACIT-F and FAACT questionnaires, respectively, demonstrated good internal consistency reliability, validity, and responsiveness (also referred to as the Simplified Evaluation of Fatigue (SEF) and Simplified Evaluation of Appetite (SEA), respectively). The estimated important difference for each scale was 1-2 points.

Conclusions: These brief scales provide the psychometric properties necessary to promote future research in NSCLC patients with CACS. Additional work should examine the clinical utility of these scales and their impact on treatment decision-making.

References

    1. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–495. doi: 10.1016/S1470-2045(10)70218-7.
    1. Kern K, Norton J. Cancer cachexia. JPEN J Parenter Enteral Nutr. 1988;12:286–298. doi: 10.1177/0148607188012003286.
    1. Johns N, Stephens NA, Fearon KCH. Muscle wasting in cancer. Int J Biochem Cell Biol. 2013;45:2215–2229. doi: 10.1016/j.biocel.2013.05.032.
    1. World Health Organization (2013) Cancer - Fact sheet No. 297. In: Editor (ed)^(eds) Book Cancer - Fact sheet No. 297, City
    1. Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with advanced non-small cell lung cancer. J Clin Oncol. 2010;28:2191–2197. doi: 10.1200/JCO.2009.25.4052.
    1. Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, Smith IE, O’Brien MER. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer. 2004;90:1905–1911. doi: 10.1038/sj.bjc.6601781.
    1. Del Ferraro C, Grant M, Koczywas M, Dorr-Uyemura LA. Management of anorexia-cachexia in late-stage lung cancer patients. J Hosp Palliat Nurs. 2012;14:397–402. doi: 10.1097/NJH.0b013e31825f3470.
    1. Wallengren O, Lundholm K, Bosaeus I. Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer. 2013;21:1569–1577. doi: 10.1007/s00520-012-1697-z.
    1. Currow DC, Abernethy AP (2014) Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome Future Oncol: 1–14
    1. Garcia J, Boccia RV, Graham C, Kumor K, Polvino W. A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia. J Clin Oncol. 2007;18:9133.
    1. Garcia J, Friend J, Allen S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer. 2013;21:129–137. doi: 10.1007/s00520-012-1500-1.
    1. Temel J, Bondarde S, Jain M, Allen S, Mann W (2013) Efficacy and safety of anamorelin HCl in NSCLC patients: results from a randomized, double-blind, placebo-controlled, multicenter phase II study. European Cancer Congress. Amsterdam, The Netherlands,1308 In: Editor (ed)^(eds) Book Efficacy and safety of anamorelin HCl in NSCLC patients: results from a randomized, double-blind, placebo-controlled, multicenter phase II study. European Cancer Congress. Amsterdam, The Netherlands,1308 City
    1. Temel J, Bondarde S, Jain M, Yan Y, Duus EM, Allen S, Mann W (2013) Evaluation of quality of life from a phase II study of anamorelin HCl in NSCLC patients. 2013 ASCO’s Quality Care Symposium. In: Editor (ed)^(eds) Book Evaluation of quality of life from a phase II study of anamorelin HCl in NSCLC patients. 2013 ASCO’s Quality Care Symposium, City
    1. Abernethy AP, Temel JS, Currow D (2013) Phase III clinical trials with anamorelin HCl, a novel oral treatment for NSCLC cachexia. In: Editor (ed)^(eds) Book Phase III clinical trials with anamorelin HCl, a novel oral treatment for NSCLC cachexia, City
    1. Grand S. Color-word interference: an investigation of the role of vocal conflict and hunger in associative priming. J Exp Psychol. 1968;77:31–40. doi: 10.1037/h0025759.
    1. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J (1993) The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. Journal of Clinical Oncology 11:570–579
    1. Smith E, Lai JS, Cella D. Building a measure of fatigue: the functional assessment of chronic illness therapy fatigue scale. PM R. 2010;2:359–363. doi: 10.1016/j.pmrj.2010.04.017.
    1. Ribaudo JM, Cella D, Hahn EA, Lloyd SR, Tchekmedyian NS, Von Roenn J, Leslie WT. Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual Life Res. 2000;9:1137–1146. doi: 10.1023/A:1016670403148.
    1. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manag. 2002;24:547–561. doi: 10.1016/S0885-3924(02)00529-8.
    1. Eton D, Cella D, Yount S, Peterman A, Neuberg D, Sledge GW, Wood W. A combination of distribution and anchor-based approaches determined minimally important differences (MIDs) for four endpoints ina breast cancer scale. J Clin Epidemiol. 2004;57:898–910. doi: 10.1016/j.jclinepi.2004.01.012.
    1. Yost KJ, Eton DT, Garcia SF, Cella D. Minimally important differences were estimated for six patient-reported outcomes measurement information system-cancer scales in advanced-stage cancer patients. J Clin Epidemiol. 2011;64:507–516. doi: 10.1016/j.jclinepi.2010.11.018.
    1. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manag. 1997;13:63–74. doi: 10.1016/S0885-3924(96)00274-6.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi